Analysts at StockNews.com started coverage on shares of Oragenics (NYSE:OGEN – Get Free Report) in a report issued on Wednesday. The firm set a “sell” rating on the stock.
Oragenics Trading Down 2.8 %
Shares of OGEN stock opened at $1.06 on Wednesday. Oragenics has a 12 month low of $1.02 and a 12 month high of $7.74. The firm has a market capitalization of $4.75 million, a price-to-earnings ratio of -0.11 and a beta of 0.31. The stock’s 50 day simple moving average is $1.78.
Oragenics (NYSE:OGEN – Get Free Report) last issued its quarterly earnings results on Friday, March 29th. The company reported ($5.48) EPS for the quarter.
Oragenics Company Profile
Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.
Recommended Stories
- Five stocks we like better than Oragenics
- How to Effectively Use the MarketBeat Ratings Screener
- Hasbro’s Management Made All the Right Calls This Quarter
- What is the Dow Jones Industrial Average (DJIA)?
- Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower Prices
- How to invest in blue chip stocks
- Power Surge: Utilities Sector’s Resilience Shines
Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.
